packageEfalizumab

efalizumab

Extends from Pharmacolibrary.Interfaces.PartialSubstance (Identity and physicochemical constants of one drug (Drugs.Substances)).

Information

Efalizumab, a monoclonal antibody immunosuppressant, was used to treat psoriasis. It was withdrawn from the market, including in the European Union, and is no longer in use.

Summary written by glm-5.3-flash from Wikidata Q418270 and the WHO ATC classification and the EMA medicines list; not checked by a person.

name:efalizumab
ATC codes:L04AA21, L04AG02
DrugBank:DB00095
Wikidata:Q418270

Parameters

TypeNameDefaultDescription
Stringname (from PartialSubstance)""INN / common name
String[:]atcCodes (from PartialSubstance)fill("", 0)all WHO ATC codes of the drug
StringdrugbankId (from PartialSubstance)""e.g. DB00758
StringpubchemCid (from PartialSubstance)""PubChem compound id
StringchebiId (from PartialSubstance)""ChEBI id (number)
StringwikidataId (from PartialSubstance)""e.g. Q410238
Stringformula (from PartialSubstance)""molecular formula
Modelica.Units.SI.MolarMassM (from PartialSubstance)0molar mass; 0 = unknown
ReallogP (from PartialSubstance)Modelica.Constants.infoctanol-water partition coefficient (log10); inf = unknown